Richard Boswell - 02 Apr 2021 Form 4 Insider Report for CEN BIOTECH INC

Reporting relationship: Senior Executive VP, Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 02 Apr 2021
Net transaction value: -$20,000
SEC form: 4
Accepted by SEC: 03 Jun 2021, 08:39:35 UTC
Source filing: View source filing
Reporting owner signature: /s/ Richard Boswell

Key filing fact

Richard Boswell filed Form 4 for CEN BIOTECH INC on 03 Jun 2021.

Key facts

This page summarizes Richard Boswell's Form 4 filing for CEN BIOTECH INC.
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Jun 2021, 08:39.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$20,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CENBF transaction

Common Stock

Sale

Transaction value: $15,000
Shares: -37,500
Change %: -0.62%
Price: $0.4000^*
Shares after: 6,000,000
Date: 26 Jan 2021
Ownership: Direct

CENBF transaction

Common Stock

Sale

Transaction value: $5,000
Shares: -6,250
Change %: -0.1%
Price: $0.8000^*
Shares after: 6,000,000
Date: 27 Jan 2021
Ownership: Direct

CENBF transaction

Common Stock

Award

Transaction value: $0
Shares: +2,185,679
Change %: +57%
Price: $0.000000
Shares after: 6,000,000
Date: 02 Apr 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

2,185,679 shares of common stock of issuer were granted by the issuer on April 2, 2021, pursuant to a restricted stock agreement pursuant to the issuer's equity compensation plan and the issuance was approved by the issuer's full board of directors.